NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Modulation of Anti-tumor T Cell Responses in Cancer Patients Treated by Concomitant Radiochemotherapy

CompletedNA

Sponsor: Centre Hospitalier Universitaire de Besancon

Conditions: Lung Cancer, Head and Neck Cancer

Interventions: Biological samples

Countries: France

The aim of this study is to evaluate modulation of anti-tumor T cell responses in cancer patients treated by concomitant radiochemotherapy (i-RTCT)

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria:

* Histologically confirmed NSCLC (Non Small Cell Lung Cancer) or SCLC (small cell lung cancer) OR histologically confirmed Head and neck cancer
* Patient candidate to a first-line concomitant radiochemotherapy
* Written informed consent

Exclusion Criteria:

* Sequential radiochemotherapy, exclusive radiotherapy, or stereotactic radiotherapy
* History of adjuvant radiochemotherapy for cancer treatment
* Patients under immunotherapy, chemotherapy or other immunosuppressive drugs (prednisone or prednisolone ≤ 10 mg/day is allowed)
* HIV, hepatitis C or B virus
* Patients with any medical or psychiatric condition or disease,
* Patients under guardianship, curatorship or under the protection of justice.

Locations (4)

Besançon, France, France
Dijon, France
Montbéliard, France
Reims, France